Causal structures for evaluating statin class effects.
Seeger
John D
JD
D000069059:Atorvastatin; D015415:Biomarkers / Q000032:analysis; D008078:Cholesterol, LDL / Q000097:blood*; D016527:Drug Costs; D011307:Drug Prescriptions; D005569:Formularies as Topic; D006279:Health Maintenance Organizations; D006538:Heptanoic Acids / Q000009:adverse effects / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000145:classification* / Q000494:pharmacology* / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000517:prevention & control*; D011758:Pyrroles / Q000009:adverse effects / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D012306:Risk
D015415:Biomarkers; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin